ERIS Lifesciences Ltd

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling a more attractive entry point for investors. Despite a recent 3.62% decline in its share price to ₹1,375.60, the pharmaceutical and biotechnology company’s improved price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages suggest a recalibration of market expectations amid broader sector dynamics.

ERIS Lifesciences Ltd., a speciality pharmaceutical company focused on chronic therapies, reported a consolidated net profit of ₹142.39 crores for Q1 FY27 ended June 2026, marking a sequential decline of 49.44% from ₹281.61 crores in Q4 FY26, though registering a year-on-year growth of 20.68% from ₹117.99 crores in Q1 FY26. The sharp quarter-on-quarter decline was primarily driven by an exceptional tax credit of ₹119.69 crores in the previous quarter, which artificially inflated Q4 FY26 profits. The stock, with a market capitalisation of ₹19,328 crores, closed at ₹1,427.20 on July 29, 2026, up 2.57% from its previous close, though it remains down 20.50% over the past year.

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 25 July 2026, providing investors with the latest insights into its performance and outlook.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite this, several technical indicators present a nuanced picture, with weekly and monthly signals diverging, reflecting a complex market sentiment for this pharmaceuticals and biotechnology small-cap stock.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, reflecting a nuanced market sentiment for the pharmaceutical and biotechnology small-cap stock.

ERIS Lifesciences Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. While some indicators suggest emerging bullishness, others point to caution, reflecting a complex market sentiment for this small-cap pharmaceutical player.

ERIS Lifesciences Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively suggest cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 July 2026, providing investors with the most up-to-date view of the company's fundamentals, returns, and market standing.

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 03 July 2026, providing investors with an up-to-date analysis of the company’s standing.

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

ERIS Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite recent price softness, the company’s improving financial trends and stable quality parameters underpin this revised stance, signalling cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

ERIS Lifesciences Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend, as reflected in recent indicator readings. Despite a modest day gain of 0.29%, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum indicators, suggesting cautious investor sentiment amid broader sector challenges.

ERIS Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 5 June 2026. This change reflects a combination of deteriorating technical indicators, a shift in valuation metrics, and mixed financial trends despite recent positive quarterly results. The company’s Mojo Score now stands at 47.0, signalling caution for investors amid a challenging market backdrop.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bearish to a more pronounced bearish trend. The company’s stock price has declined modestly in recent sessions, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade to Sell.

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and presents a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector. Despite a modest day decline of 0.48%, the company’s valuation metrics and comparative analysis against peers and historical benchmarks offer valuable insights for investors navigating a complex market environment.